Sensitivity to injected cholera toxin of the sodium efflux in single barnacle muscle fibers.
A study has been made of the effect of microinjected cholera toxin (CT) on the efflux in single barnacle muscle fibers. Characteristically, injected CT causes sustained stimulation of the ouabain-insensitive Na efflux but only after a lag phase. An effect is seen with as little as a 10(-7) M-solution of CT. Sustained stimulation after a lag phase is also seen following injection of subunit A fragment. Enrichment of fibers with NAD+ fails to enhance the response to CT. Prior injection of GTP or its non-hydrolyzeable analogue, Gpp(NH)p, markedly reduces the response to CT, whilst prior injection of CT reduces the response to guanine nucleotides. Evidence is also brought forward that omission of external Ca2+ reversibly reduces the response to CT and that pre- or postinjection of EGTA markedly reduces the response to CT. In addition, fibers preinjected with CT show increased aequorin light emission. Whereas verapamil and Cd2+ are ineffective, both Mg2+ and trace metals, e.g. Fe and Zn, reverse the response to CT following injection. Prior injection of protein kinase inhibitor reduces the response to CT. As for calmodulin inhibitors, e.g. chlorpromazine, imipramine and mepacrine, they are effective in reducing the response to CT but not calmodulin antibody (IgG). Collectively, the above results are compatible with the view that sustained stimulation of the ouabain-insensitive Na efflux by injected CT is due to persistent activation of adenylate cyclase by the toxin and that a fall in myoplasmic pCa facilitates or augments this activation mechanism.
D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D002104:Cadmium / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D002147:Calmodulin / Q000037:antagonists & inhibitors; D002352:Carrier Proteins / Q000494:pharmacology; D002772:Cholera Toxin / Q000494:pharmacology*; D004492:Edetic Acid / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D006160:Guanosine Triphosphate / Q000494:pharmacology; D006165:Guanylyl Imidodiphosphate / Q000494:pharmacology; D066298:In Vitro Techniques; D047908:Intracellular Signaling Peptides and Proteins; D007473:Ion Channels / Q000378:metabolism*; D007501:Iron / Q000494:pharmacology; D008274:Magnesium / Q000494:pharmacology; D008566:Membranes / Q000201:enzymology; D009132:Muscles / Q000378:metabolism*; D009243:NAD / Q000494:pharmacology; D010042:Ouabain; D012964:Sodium / Q000378:metabolism*; D001468:Thoracica / Q000378:metabolism*; D014700:Verapamil / Q000494:pharmacology; D015032:Zinc / Q000494:pharmacology
D002147:Calmodulin; D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D007473:Ion Channels; C015482:protein kinase modulator; D002104:Cadmium; D009243:NAD; D006165:Guanylyl Imidodiphosphate; D004533:Egtazic Acid; D010042:Ouabain; D006160:Guanosine Triphosphate; D002772:Cholera Toxin; D004492:Edetic Acid; D012964:Sodium; D014700:Verapamil; D007501:Iron; D000262:Adenylyl Cyclases; D008274:Magnesium; D015032:Zinc; D002118:Calcium